Cargando…
CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?
Autoimmunity remains a complex physiologic deviation, enabled and perpetuated by a variety of interplayers and pathways. Simplistic approaches, targeting either isolated end-effectors of more centrally placed interactors of these mechanisms, are continuously tried in an effort to comprehend and halt...
Autores principales: | Pateinakis, Panagiotis, Pyrpasopoulou, Athina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985174/ https://www.ncbi.nlm.nih.gov/pubmed/24791010 http://dx.doi.org/10.1155/2014/973609 |
Ejemplares similares
-
Targeting the B-Cell Pathway in Lupus Nephritis: Current Evidence and Future Perspectives
por: Pateinakis, Panagiotis, et al.
Publicado: (2013) -
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
por: Baker, D., et al.
Publicado: (2020) -
Effect of TACI Signaling on Humoral Immunity and Autoimmune Diseases
por: Zhang, Yi, et al.
Publicado: (2015) -
Humoral and Cellular Immune Responses to SARS–CoV‐2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion
por: Simon, David, et al.
Publicado: (2021) -
Cardiorenal Syndrome Type 4—Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management
por: Pateinakis, Panagiotis, et al.
Publicado: (2011)